Physician profile
Muhammad H Bashir
NPI 1053613711
$4,648.84
in general payments reported to CMS, 2019-2025
30 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $1,497 · 2021: $488 · 2022: $725 · 2023: $901 · 2024: $347 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $851.39 | 2020-2023 | Takhzyro, Cuvitru |
| Octapharma USA, INC. | $832.36 | 2019-2025 | Cutaquig |
| Astrazeneca Pharmaceuticals Lp | $639.38 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $384.75 | 2019-2025 | Nucala, Trelegy Ellipta |
| Biocryst US Sales Co., LLC | $284.54 | 2021-2025 | Orladeyo |
| Csl Behring | $279.36 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $243.72 | 2022-2025 | |
| Zimmer Biomet Holdings, INC. | $147.81 | 2024 | Htr-Pekk |
| Novartis Pharmaceuticals Corporation | $100.61 | 2019-2025 | |
| Kaleo, INC. | $98.06 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.01 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $70.75 | 2025 | Neffy |
| Amgen INC. | $69.80 | 2022-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $68.54 | 2021-2024 | Dupixent |
| Optinose US, INC. | $67.13 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.36 | 2019-2022 | |
| Incyte Corporation | $52.41 | 2021-2024 | Opzelura |
| Bio Products Laboratory USA, INC. | $41.72 | 2022-2023 | Gammaplex, Coagadex |
| Greer Laboratories, INC. | $40.49 | 2024-2025 | Oralair |
| Aimmune Therapeutics, INC. | $38.19 | 2021-2022 | |
| Abbvie INC. | $29.55 | 2023 | Rinvoq |
| Leo Pharma INC. | $25.86 | 2022 | |
| Horizon Therapeutics Plc | $25.00 | 2020 | |
| Mylan Specialty L.P. | $22.94 | 2023 | Yupelri |
| Grifols USA, LLC | $21.95 | 2023 | Xembify |
| Pfizer INC. | $20.77 | 2021 | |
| Uswm, LLC | $19.54 | 2021 | |
| Pharming Healthcare, INC. | $18.39 | 2021 | |
| Shire North American Group INC | $18.08 | 2019 | |
| Merck Sharp & Dohme LLC | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.